The routine inspection, which took place over four days, from September 13th - September 16th, was conducted by a MHRA inspector who concluded that the site continues to be compliant with EU Good Manufacturing Practices, with no critical or major failures observed.
Commenting on the inspection, Paul O'Connor (Vice President, Quality), said:
"We are extremely pleased with the outcome of our inspection. These successful results are a positive reflection of all the investment Almac has made over the past few years in our facilities and recruitment of the best employees, ensuring that we are a market leader and continue to deliver a high quality service. Quality is at the core of our ethos - we have three MHRA approved facilities globally, including our additional FDA assessed US facilities in Audubon, Pennsylvania and Durham, North Carolina. The very high standards of quality compliance will continue with our new $120 million North American Headquarters in Souderton - scheduled to open during the autumn."
Notes to Editors
The Almac Group comprises five closely integrated divisions offering a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRS technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.
The company employs over 2,800 individuals and is headquartered in
Craigavon, Northern Ireland. US operations are based in Pennsylvania, North
Carolina and California. Almac has officially gained full possession of its
new $120m Nor
|SOURCE Almac Group|
Copyright©2010 PR Newswire.
All rights reserved